Observational Study of Characteristics, Treatment and Outcomes with Severe Asthma in the United States (CHRONICLE)

Study identifier:D3250R00023

ClinicalTrials.gov identifier:NCT03373045

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

The CHRONICLE Study: A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals with Severe Asthma in the United States

Medical condition

asthma

Phase

N/A

Healthy volunteers

Study drug

Sex

All

Estimated Enrollment

5000

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 27 Feb 2018

Estimated Primary Completion Date: 30 Jun 2026

Estimated Study Completion Date: 30 Jun 2026

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: -

Verification:

Verified 01 Mar 2024 by AstraZeneca

Collaborators

PAREXEL, MedImmune

Inclusion and exclusion criteria

Inclusion Criteria

:
1. Individuals with a diagnosis of severe asthma for at least 12 months prior to enrollment and confirmed by the Investigator not to be due to alternative diagnoses.
2. Currently receiving care from specialist physicians (eg, pulmonologists and or allergists) at the Investigator’s or sub–investigator’s site.
3. 18 years of age and older.
4. Meeting at least one of the following three criteria (a, b, or c):
a. Uncontrolled asthma while receiving high-dose ICS with additional controllers.
i. Uncontrolled is defined by meeting at least one of the following (as outlined by ATS/ERS [American Thoracic Society/European Respiratory Society] guidelines):
1. Poor symptom control: Asthma Control Questionnaire consistently ≥1.5, ACT <20 (or “not well controlled” by NAEPP [National Asthma Education and Prevention Program]/Global Initiative for Asthma guidelines).
2. Frequent severe exacerbations: two or more bursts of systemic corticosteroids (≥3 days each) in the previous 12 months.
3. Serious exacerbations: at least one hospitalization, intensive care unit stay or mechanical ventilation in the previous 12 months.
4. Airflow limitation: after appropriate bronchodilator withhold FEV1 <80% predicted (in the face of reduced FEV1/FVC defined as less than the lower limit of normal).
ii. For the purposes of this study, high–dose ICS will be defined as
1. ICS at a cumulative dose of >500 μg fluticasone propionate equivalents daily as defined in Appendix A, or
2. Highest labeled dose of a combination of ICS/LABA.
b. Current use of a Food and Drug Administration (FDA)–approved monoclonal antibody agent for treatment of severe asthma (use is not primarily for an alternative condition).
c. Use of systemic corticosteroids or other systemic immunosuppressants (any dose level) for approximately 50% or more of the prior 12 months for treatment of severe asthma (use is not primarily for an alternative condition).

Exclusion Criteria

1. Not willing and able to sign written informed consent. Consent can be obtained from having a responsible, legally authorized representative acting on patient’s behalf.
2. Not fluent in English or Spanish.
3. Inability to complete study follow–up or web–based PROs. If the patient does not have email or web access, minimal assistance from others to access the web–based PRO is permitted (ie receiving the email and/or assisting patient in navigating to the web page); PROs must be completed by the patient.
4. Received an investigational therapy for asthma, allergy, atopic disease, or eosinophilic disease as part of a clinical trial during the 6 months prior to enrollment.
a. Once enrolled in the CHRONICLE Study, patients can enroll in trials of investigational therapies (as well as other non–interventional studies) as long as they continue to complete study follow–up. If a patient enrolls in a trial of an investigational therapy, the identity (National Clinical Trial [NCT] number) of the study and dates of the first and last investigational therapy administrations will be collected. If a patient receives blinded therapy in a trial, the Investigator will request the identity of that therapy at trial conclusion so that treatment information collected for the current study may be updated accordingly.

The CHRONICLE Study is a multi-center, non-interventional, prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and/or require systemic corticosteroid or monoclonal antibody therapy. This study will provide a contemporary description of the epidemiology and medical management of United States adults with severe asthma who have not achieved control with high-dose ICS therapy and additional controllers. Additionally, the study will describe the use of and outcomes associated with recently approved monoclonal antibody therapies for severe asthma. Patients will be enrolled from a diverse population of academic and community-based specialist centers across the US. Data will be collected in a naturalistic manner and patient management will not be influenced by the study protocol. At least 1500 patients in the US with a confirmed diagnosis of severe asthma will be enrolled by a diverse set of asthma specialists (eg, allergists and pulmonologists who treat asthma) from academic and community-based centers. Basic de-identified information will be collected for all patients meeting study inclusion criteria, including those not approached for enrollment or who decline enrollment, to enable an assessment of the enrolled and non-enrolled populations. This information will include age, sex, insurance status, age at asthma diagnosis, class of asthma treatment per study inclusion criteria, number of asthma exacerbations in the past 12 months, study eligibility, whether the patient was approached for enrollment, study enrollment status, and reason for not enrolling for those who are approached but do not enroll. Patient-reported asthma control (Asthma Control Test [ACT]), asthma exacerbations, and treatment adherence will be solicited monthly. Patient-reported information on asthma-related healthcare utilization, global evaluation of treatment effectiveness (GETE), and work productivity (Work Productivity and Activity Impairment Asthma questionnaire [WPAI-Asthma]) will be collected at baseline and approximately every 3 months. Detailed information on asthma-related quality of life (Saint George’s Respiratory Questionnaire [SGRQ]) as well as presence of an asthma treatment plan will be collected from patients approximately every 6 months. All of the questionnaires will be collected via web-based surveys. Patients will then be followed until study discontinuation or the patient withdraws from the study or death, whichever occurs first. The expectation is that patients will be followed for a period of at least 3 years.

Sort by status

No locations available

Arms	Assigned Interventions
Cohort of US adults with severe asthma To describe patient characteristics, treatment patterns, and health outcomes among a large, geographically diverse cohort of US adults with severe asthma who are not controlled on high-dose ICS with additional controllers and/or require chronic systemic corticosteroid or monoclonal antibody therapy.	-

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

[email protected]